Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

Simon Chowdhury, MA, MBBS, MRCP, PhD
Published: Wednesday, Jul 12, 2017



Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Pazopanib is a standard first-line treatment and will remain as such, until additional data are reported out. However, Chowdhury adds that pazopanib could be combined with other immunotherapies aside from pembrolizumab that work differently.

Regarding pembrolizumab, there are promising combination data with axitinib (Inlyta)—a regimen now being explored in a phase III study in the frontline setting. 


Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Pazopanib is a standard first-line treatment and will remain as such, until additional data are reported out. However, Chowdhury adds that pazopanib could be combined with other immunotherapies aside from pembrolizumab that work differently.

Regarding pembrolizumab, there are promising combination data with axitinib (Inlyta)—a regimen now being explored in a phase III study in the frontline setting. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x